AgonOx partners with MedImmune to advance immune system activators in cancer therapy
This article was originally published in Scrip
Executive Summary
AgonOx, a Portland, Oregon-based private company, has entered into an exclusive, global partnership with MedImmune, the biologics arm of AstraZeneca, to advance immune stimulators based on AgonOx's OX40 platform covering agonists that stimulate tumour-specific T cell immunity.